GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valbiotis SA (FRA:8JD) » Definitions » EV-to-EBIT

Valbiotis (FRA:8JD) EV-to-EBIT : -1.28 (As of May. 28, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Valbiotis EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Valbiotis's Enterprise Value is €12.46 Mil. Valbiotis's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-9.76 Mil. Therefore, Valbiotis's EV-to-EBIT for today is -1.28.

The historical rank and industry rank for Valbiotis's EV-to-EBIT or its related term are showing as below:

FRA:8JD' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.27   Med: -3.33   Max: 0.63
Current: -1.28

During the past 10 years, the highest EV-to-EBIT of Valbiotis was 0.63. The lowest was -15.27. And the median was -3.33.

FRA:8JD's EV-to-EBIT is ranked worse than
100% of 477 companies
in the Biotechnology industry
Industry Median: 8.27 vs FRA:8JD: -1.28

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Valbiotis's Enterprise Value for the quarter that ended in Dec. 2024 was €15.77 Mil. Valbiotis's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-9.76 Mil. Valbiotis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -61.88%.


Valbiotis EV-to-EBIT Historical Data

The historical data trend for Valbiotis's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valbiotis EV-to-EBIT Chart

Valbiotis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.45 -6.19 -2.57 -8.50 -1.86

Valbiotis Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.57 - -8.50 - -1.86

Competitive Comparison of Valbiotis's EV-to-EBIT

For the Biotechnology subindustry, Valbiotis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valbiotis's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valbiotis's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Valbiotis's EV-to-EBIT falls into.


;
;

Valbiotis EV-to-EBIT Calculation

Valbiotis's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=12.460/-9.759
=-1.28

Valbiotis's current Enterprise Value is €12.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valbiotis's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-9.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valbiotis  (FRA:8JD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Valbiotis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=-9.759/15.771324
=-61.88 %

Valbiotis's Enterprise Value for the quarter that ended in Dec. 2024 was €15.77 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valbiotis's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-9.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valbiotis EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Valbiotis's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Valbiotis Business Description

Traded in Other Exchanges
Address
12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of major metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.

Valbiotis Headlines

No Headlines